<DOC>
	<DOCNO>NCT00000743</DOCNO>
	<brief_summary>To determine safety tolerance alvircept sudotox ( sCD4-PE40 ) give various dose interval concentration . To determine whether frequent dose alters immunogenicity toxicity . To obtain preliminary data ascertain whether sCD4-PE40 activity HIV human subject . To determine whether additive toxicity combine use sCD4-PE40 zidovudine ( AZT ) . There evidence AZT sCD4-PE40 , experimental drug anti-HIV activity previously demonstrate vitro , may produce increased benefit use combination HIV-infected patient .</brief_summary>
	<brief_title>A Phase I , Dose-Escalating Safety Tolerance Study sCD4-PE40 HIV-Infected Persons</brief_title>
	<detailed_description>There evidence AZT sCD4-PE40 , experimental drug anti-HIV activity previously demonstrate vitro , may produce increased benefit use combination HIV-infected patient . Cohorts six patient receive escalate dos sCD4-PE40 single IV weekly dose 8 week . All six patient give dose must complete 2 week therapy without dose-limiting toxicity dose escalation subsequent patient cohort may occur . The MTD define dose sCD4-PE40 immediately two six patient experience grade 3 high toxicity one six patient experience grade 4 toxicity . After MTD once-weekly schedule reach , subsequent cohort receive escalate dos sCD4-PE40 5x weekly schedule approximately 4 week , attempt establish MTD schedule . When MTD determine 5x weekly schedule , antiretroviral activity observe , six additional patient receive dose combine AZT 4 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis aerosolized pentamidine , trimethoprim / sulfamethoxazole , dapsone . Clotrimazole troches nystatin oral suspension oral candidiasis . Acyclovir ( 1000 mg/day 10 day ) herpes lesion . Erythropoietin . Patients must : Documented HIV infection ELISA confirm second method . If prior diagnosis AIDS establish CDC criterion , confirmatory test require . CD4 count = &lt; 300 cells/mm3 within 4 week prior study entry . Positive p24 antigen . Patients enter AZT portion study : Must AZT naive less 2 month AZT therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Hemophilia . Acute medical problem ( include active opportunistic infection active cryptococcosis , Pneumocystis carinii , herpes zoster , histoplasmosis , CMV nonopportunistic disease include liver disease , renal disease , orthostatic hypotension ) time study entry . Active pulmonary disease . Chronic active hepatitis B surface antigenemia unstable hepatitis C. Current diagnosis malignancy systemic therapy would require study . Inadequate intravenous access . Concurrent Medication : Excluded : Hepatotoxic agent . Other antiretroviral immunomodulator agent ( include limit AZT , ddI , ddC , interferon , steroid ) . Other investigational drug . Systemic therapy malignancy . GCSF GMCSF . Prior Medication : Excluded : Other antiretroviral immunomodulator agent ( include limit AZT , ddI , ddC , interferon , steroid ) within 4 week prior study entry . Ribavirin within 90 day prior study entry . Cytotoxic chemotherapy within one month prior study entry . Prior soluble CD4 CD4Ig . Excluded patient enter AZT portion study : More 2 month prior AZT therapy . Current active alcoholism active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>